Program

BIOPROCESSING & MANUFACTURING STARTEGIES

Innovations in Process Development and Manufacturing Driving the Future of ATMP development: Avoid pitfalls and reduce bottlenecks, implementing new breakthrough Cell & Gene Therapy processing methodologies, technologies and approaches to improve quality, yield and capacity. Achieving commercial scalability with ‘facilities of the future’ in patient-specific therapies: Develop a “fit-for-purpose” development pathway that is associated with “faster to market” options for clinical development. Fundamental evolution to meet ATMP Quality and Process Challenges: Implementation of next generation digital bioprocessing 4.0 and integrating automation technology for Increased GMP compliance and consistency. Enabling acceleration of processing research and scale-up considerations. Process and analytical development for complex cell and gene therapy products: Best techniques in managing the development and production of very complex products, by utilizing a combination of traditional downstream approaches and new novel technologies, establishing scalable and robust purification processes for cell and gene therapy products.

NEXT GEN CELL, GENE AND CAR-T DEVELOPMENT AMPT COMMERCIAL, REGULATORY, SUPPLY CHAIN AND R&D INNOVATION Proudly presenting this years highly anticipated and exciting CGT-development 2024 Innovation Summit program; Comprised of fully renowned world class speaker and industry thought leaders. Following a comprehensive research process undertaken with an expert panel of advisory board and results from delegates surveys. The program is rich with robust content on innovation and pivotal breakthroughs; giving you insight on the latest industry trends and technologies impacting growth in the Cell and Gene Therapy's market. As Cell & Gene Therapy products are moving from niche to mainstream, the industry is facing a paradigm shift in cost, quality, complexity, and scale creating opportunities to develop new and different technologies and operating models. Achieving the next phase of the industry potential will require a further revolution, not only in the laboratory but also in strategy, technology, and operations. Decisions made today will affect companies' competitive positions years or even decades into the future. Access the unparalleled wisdom of inside knowledge from leading companies such as Pfizer and GSK. Industry peers give presentations and case studies on success in overcoming key challenges and bottlenecks. Engage interactively with globally renowned leaders in round table group sessions and panel discussion. Key Topics of significants gains from deployment of technological innovation and techniques.

A compiling program that reflects key strategic issues that senior executives have identified

Intelligence that flourishes within Cell Gene Therapy communities.

Gene therapy coming of age - Commercial opportunities and getting ahead the upcoming challenges: Recalibration in development of reimbursement model for therapies that go beyond the traditional approach to disease treatment. Regulatory pathway and novel pricing & reimbursement mechanisms for the US and further afield. Understanding all strategic options in an unprecedented era of expedited regulatory pathways: Examining and defining the potential value for industry in accelerated development and conditional approval pathways from around the globe. Examining critical factors and potential threats for continued innovation in Cell and Gene therapies: Overcoming bottlenecks and innovation barriers. Development of commercial manufacturing strategies: Cell Therapy Scale-Up Strategies For Commercial Success Alternative sources of investment: Where are the most significant opportunities for both cell & gene therapy start-ups and mature biotechs today?. Addressing The Complexity Of Process Validation For Cell And Gene Therapy Products

QUALITY, SUPPLY CHAIN, COMMERCIALISATION

Immunotherapy and targeted therapy spheres: Which combination therapy strategies will help realize the full potential? Honing combination therapy clinical strategies involving CAR T cell and TCR immunotherapy products Candidate. Adoptive T cell immunotherapy business models: Who has the lead in removing barriers to commercial success? Addressing the most pressing challenges facing the adoptive T cell therapy space today. Will Allogeniec Replace Autologous Therapies? Current industry trends and innovation focuses. Enabling more Precise, Efficient and Safer Genome Editing & Quantifying its Outcomes: Innovation in repurposing of CRISPR-Cas 9 and all its variants. NextGen tools for on and off target effects when using different enzymes & variants Novel Gene Editing Applications in CART: Understand next generations technologies in adoptive T cell Immunotherapy

Rene Labatut Vice President of Global Manufacturing Technology Sanofi Pasteur

David Roush PhD Senior Principal Scientist Protein Purification Merck & Co

Micheal Washabaough CSO AdelloBio

Jörg Thömmes SVP Pharmaceutical Sciences & Technology Bill & Melinda Gates Foundation

Dr Jesper Johanson Senior CMC Project Manager Novo Nordisk

“Learn, Debate And Bench Mark With Some Of The Most Influential Leaders In Cell & Gene Therapy Globally”

Do you have someone in mind who could feature on the panel discussion? Are you a fan of a particular speaker or perhaps would like to take a seat on the panel yourself.

Send your recommendations to the Producer and receive a special congress booking code.

Innovate World Class speaker with the highest Credentials delivering unrivaled insight make up our compiling programs, if you would like to present to an interactive audience of pioneering industry leaders please contact

Collaborate Our summits are specially designed for company elites and span the entire Pharmaceutical and Life Science realm. For group bookings or an annual global members pass card please contact

Advance Market leaders with cutting edge capabilities present great innovation. If end users gain a distinct advantage by using your product or services please contact

Delegates Inquisitions.

BIOPROCESSING & MANUFACTURING STARTEGIES

Innovations in Process Development and Manufacturing Driving the Future of ATMP development: Avoid pitfalls and reduce bottlenecks, implementing new breakthrough Cell & Gene Therapy processing methodologies, technologies and approaches to improve quality, yield and capacity. Achieving commercial scalability with ‘facilities of the future’ in patient-specific therapies: Develop a “fit-for-purpose” development pathway that is associated with “faster to market” options for clinical development. Fundamental evolution to meet ATMP Quality and Process Challenges: Implementation of next generation digital bioprocessing 4.0 and integrating automation technology for Increased GMP compliance and consistency. Enabling acceleration of processing research and scale-up considerations. Process and analytical development for complex cell and gene therapy products: Best techniques in managing the development and production of very complex products, by utilizing a combination of traditional downstream approaches and new novel technologies, establishing scalable and robust purification processes for cell and gene therapy products.

NEXT GEN CELL, GENE AND CAR-T DEVELOPMENT AMPT COMMERCIAL, REGULATORY, SUPPLY CHAIN AND R&D INNOVATION Proudly presenting this years highly anticipated and exciting CGT-development 2024 Innovation Summit program; Comprised of fully renowned world class speaker and industry thought leaders. Following a comprehensive research process undertaken with an expert panel of advisory board and results from delegates surveys. The program is rich with robust content on innovation and pivotal breakthroughs; giving you insight on the latest industry trends and technologies impacting growth in the Cell and Gene Therapy's market. As Cell & Gene Therapy products are moving from niche to mainstream, the industry is facing a paradigm shift in cost, quality, complexity, and scale creating opportunities to develop new and different technologies and operating models. Achieving the next phase of the industry potential will require a further revolution, not only in the laboratory but also in strategy, technology, and operations. Decisions made today will affect companies' competitive positions years or even decades into the future. Access the unparalleled wisdom of inside knowledge from leading companies such as Pfizer and GSK. Industry peers give presentations and case studies on success in overcoming key challenges and bottlenecks. Engage interactively with globally renowned leaders in round table group sessions and panel discussion. Key Topics of significants gains from deployment of technological innovation and techniques.

A compiling program that reflects key strategic issues that senior executives have identified

Intelligence that flourishes within Cell Gene Therapy communities.

Gene therapy coming of age - Commercial opportunities and getting ahead the upcoming challenges: Recalibration in development of reimbursement model for therapies that go beyond the traditional approach to disease treatment. Regulatory pathway and novel pricing & reimbursement mechanisms for the US and further afield. Understanding all strategic options in an unprecedented era of expedited regulatory pathways: Examining and defining the potential value for industry in accelerated development and conditional approval pathways from around the globe. Examining critical factors and potential threats for continued innovation in Cell and Gene therapies: Overcoming bottlenecks and innovation barriers. Development of commercial manufacturing strategies: Cell Therapy Scale-Up Strategies For Commercial Success Alternative sources of investment: Where are the most significant opportunities for both cell & gene therapy start-ups and mature biotechs today?. Addressing The Complexity Of Process Validation For Cell And Gene Therapy Products

QUALITY, SUPPLY CHAIN, COMMERCIALISATION

Immunotherapy and targeted therapy spheres: Which combination therapy strategies will help realize the full potential? Honing combination therapy clinical strategies involving CAR T cell and TCR immunotherapy products Candidate. Adoptive T cell immunotherapy business models: Who has the lead in removing barriers to commercial success? Addressing the most pressing challenges facing the adoptive T cell therapy space today. Will Allogeniec Replace Autologous Therapies? Current industry trends and innovation focuses. Enabling more Precise, Efficient and Safer Genome Editing & Quantifying its Outcomes: Innovation in repurposing of CRISPR-Cas 9 and all its variants. NextGen tools for on and off target effects when using different enzymes & variants Novel Gene Editing Applications in CART: Understand next generations technologies in adoptive T cell Immunotherapy

Rene Labatut Vice President of Global Manufacturing Technology Sanofi Pasteur

David Roush PhD Senior Principal Scientist Protein Purification Merck & Co

Micheal Washabaough CSO AdelloBio

Jörg Thömmes SVP Pharmaceutical Sciences & Technology Bill & Melinda Gates Foundation

Dr Jesper Johanson Senior CMC Project Manager Novo Nordisk